<DOC>
	<DOCNO>NCT00034515</DOCNO>
	<brief_summary>The purpose ascend dose group study ass safety , tolerability , effect multiple dose level INS37217 placebo follow five day twice daily treatment maximum tolerate dose administer inhalation via Pari LC Star nebulizer adult pediatric patient cystic fibrosis</brief_summary>
	<brief_title>A Study Adult Pediatric Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>FEV1 4070 % ( adult ) FEV1 &gt; /=50 % ( pediatrics ) oxygen saturation &gt; 90 % clinically stable willing stay overnight abnormal renal liver function receive corticosteroid exceed 10mg/day 20 mg every day receive intravenous aerosolized antibiotic 1 week prior dose</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>